About
Stephen Rapecki originated the blockbuster biologic bimekizumab from discovery to approval, combining 30 years of hands-on drug discovery at Celltech/UCB with ongoing peer-reviewed immunology research and seed-stage cofounding and advising.
Invests in
BiotechDigital HealthHealthtechMedical Devices
Experience
- MedicxiVenture Partnercurrent2023 — presentLondon, England, United Kingdom
- UCBDirector, Experimental Therapeutics2019 — 2023
- UCBHead Of Rationally Designed NBEs2018 — 2023Slough, United Kingdom
- UCBDirector Functional Screening2017 — 2023Slough, United Kingdom
- UCBSenior Group Leader2015 — 2017Slough, United Kingdom
- UCBSenior Principle Scientist2007 — 2015
- Celltech PharmaceuticalsSenior Scientist1993 — 2007Slough, United Kingdom
Education
- Kingston UniversityBachelor of Science - BS, Biomedical Sciences1988 — 1991
- Lewis Boys School1980 — 1988
Skills & more
Start-up Ventures3Early Stage Investment2Immunology11Drug Discovery13Cell Culture4Pharmacology7Clinical Development2Biopharmaceuticals6Biochemistry3Biomarkers2Drug Development5Molecular Biology3
+11 more
Monoclonal AntibodiesAssay DevelopmentAntibodiesLife SciencesBiotechnologyCell BiologyR&DCellPharmaceutical IndustryELISAIn VitroFrom Stephen's professional profile.
Same school
Also attended Kingston University23
René RechtmanInvestor at FELIX CAPITALMaria Henriques da SilvaMarketing & Brand Lead at Shilling VCHelen ClarkPartner at Piton Capital LLPAnil HansjeeGeneral Partner at Fabric VenturesRadhika KhemkaSenior Manager at Anicut CapitalAlisa MinasyanAnalyst, Life Sciences at SmartGateVC
+ 17 more
